Peter Lichtlen

Zurich, ZH, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

A Bispecific, Tetravalent Antibody Targeting Inflammatory and Pruritogenic Pathways in Atopic Dermatitis.

A Bispecific, Tetravalent Antibody Targeting Inflammatory and Pruritogenic Pathways in Atopic Dermatitis.

Journal: JID innovations : skin science from molecules to population health

Published: October 03, 2023

An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin.

An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin.

Journal: Oncoimmunology

Published: July 17, 2023

Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade.

Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade.

Journal: Oncoimmunology

Published: July 18, 2022

Correction to: Capsule and Sprinkle Formulations of Lubiprostone Are Not Biologically Similar in Patients with Functional Constipation.

Correction to: Capsule and Sprinkle Formulations of Lubiprostone Are Not Biologically Similar in Patients with Functional Constipation.

Journal: Advances in therapy

Published: May 24, 2021

Lubiprostone for Pediatric Functional Constipation: Randomized, Controlled, Double-Blind Study With Long-term Extension.

Lubiprostone for Pediatric Functional Constipation: Randomized, Controlled, Double-Blind Study With Long-term Extension.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: December 03, 2020

Capsule and Sprinkle Formulations of Lubiprostone Are Not Biologically Similar in Patients with Functional Constipation.

Capsule and Sprinkle Formulations of Lubiprostone Are Not Biologically Similar in Patients with Functional Constipation.

Journal: Advances in therapy

Published: September 15, 2020

Effects of Lubiprostone, an Intestinal Secretagogue, on Electrolyte Homeostasis in Chronic Idiopathic and Opioid-induced Constipation.

Effects of Lubiprostone, an Intestinal Secretagogue, on Electrolyte Homeostasis in Chronic Idiopathic and Opioid-induced Constipation.

Journal: Journal of clinical gastroenterology

Published: March 19, 2019

Efficacy of Lubiprostone for the Treatment of Opioid-Induced Constipation, Analyzed by Opioid Class.

Efficacy of Lubiprostone for the Treatment of Opioid-Induced Constipation, Analyzed by Opioid Class.

Journal: Pain medicine (Malden, Mass.)

Published: June 14, 2018

Unmet Needs in Pediatric Functional Constipation.

Unmet Needs in Pediatric Functional Constipation.

Journal: Clinical pediatrics

Published: May 11, 2018

The Cost Effectiveness of Lubiprostone in Chronic Idiopathic Constipation.

The Cost Effectiveness of Lubiprostone in Chronic Idiopathic Constipation.

Journal: PharmacoEconomics - open

Published: January 06, 2018

Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation.

Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation.

Journal: Alimentary pharmacology & therapeutics

Published: June 07, 2016

Lubiprostone In Chronic Idiopathic Constipation: A Cost-Effectiveness Analysis.

Lubiprostone In Chronic Idiopathic Constipation: A Cost-Effectiveness Analysis.

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Published: November 01, 2014

Showing 1-12 of 14

Last Updated: 09/26/2026